CERS MEXC RealStocks
Own real CERS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-16 09:47:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cerus Corp. (CERS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $2.04, with a market capitalization of $400.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.47 to $3.47. This page covers its latest market performance, valuation, price trends and company information.
$400.88M | |
$1.99 | |
$2.04 | |
$1.99 | |
$1.99 | |
351.00 | |
1.92M | |
-- | |
$3.47 | |
$1.47 | |
-- | |
-- |
Cerus Corp. (CERS) is trading at $2.04 in pre-market trading as of 2026-11-16 09:12:00, up 2.52% ($0.05) from the previous close of $1.99
Pre-market trading shows how investors are pricing CERS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Cerus Corp. (CERS) moved from $2.13 to $2.04, representing a decline of 4.46% ($0.09).
The stock traded between $1.91 and $2.44 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.71 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 28.3%
CERS is currently trading at $2.04, placing it 28.3% of the way from its 52-week low of $1.47 to its 52-week high of $3.47. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 345 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cerus Corp. (CERS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CERS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CERS shares and USD.
CERS Shares to USD
1.00 CERS shares = 2.035 USD
Calculations are estimates based on the latest available price and are for reference only.